124 related articles for article (PubMed ID: 30590258)
1. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Pati ML; Vitale P; Ferorelli S; Iaselli M; Miciaccia M; Boccarelli A; Di Mauro GD; Fortuna CG; Souza Domingos TF; Rodrigues Pereira da Silva LC; de Pádula M; Cabral LM; Sathler PC; Vacca A; Scilimati A; Perrone MG
Eur J Med Chem; 2019 Feb; 164():59-76. PubMed ID: 30590258
[TBL] [Abstract][Full Text] [Related]
2. A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior.
Solidoro R; Miciaccia M; Bonaccorso C; Fortuna CG; Armenise D; Centonze A; Ferorelli S; Vitale P; Rodrigues P; Guimarães R; de Oliveira A; da Paz M; Rangel L; Sathler PC; Altomare A; Perrone MG; Scilimati A
Eur J Med Chem; 2024 Feb; 266():116135. PubMed ID: 38219659
[TBL] [Abstract][Full Text] [Related]
3. An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid.
Perrone MG; Miciaccia M; Vitale P; Ferorelli S; Araújo CDCB; de Almeida GS; Souza Domingos TF; da Silva LCRP; de Pádula M; Cabral LM; Sathler PC; Bonaccorso C; Fortuna CG; Scilimati A
Eur J Med Chem; 2021 Jan; 209():112919. PubMed ID: 33129592
[TBL] [Abstract][Full Text] [Related]
4. Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier.
Perrone MG; Vitale P; Ferorelli S; Boccarelli A; Coluccia M; Pannunzio A; Campanella F; Di Mauro G; Bonaccorso C; Fortuna CG; Scilimati A
Eur J Med Chem; 2017 Dec; 141():404-416. PubMed ID: 29032033
[TBL] [Abstract][Full Text] [Related]
5. Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection.
Scilimati A; Ferorelli S; Iaselli MC; Miciaccia M; Pati ML; Fortuna CG; Aleem AM; Marnett LJ; Perrone MG
Eur J Med Chem; 2019 Oct; 179():16-25. PubMed ID: 31229884
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).
Cingolani G; Panella A; Perrone MG; Vitale P; Di Mauro G; Fortuna CG; Armen RS; Ferorelli S; Smith WL; Scilimati A
Eur J Med Chem; 2017 Sep; 138():661-668. PubMed ID: 28710965
[TBL] [Abstract][Full Text] [Related]
8. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
[TBL] [Abstract][Full Text] [Related]
9. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.
Vitale P; Perrone MG; Malerba P; Lavecchia A; Scilimati A
Eur J Med Chem; 2014 Mar; 74():606-18. PubMed ID: 24531199
[TBL] [Abstract][Full Text] [Related]
10. Exploration of isoxazole analogs: Synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling.
Hawash M; Abdallah S; Abudayyak M; Melhem Y; Abu Shamat M; Aghbar M; Çapan I; Abualhasan M; Kumar A; Kamiński M; Góral T; Dominiak PM; Sobuh S
Eur J Med Chem; 2024 May; 271():116397. PubMed ID: 38626522
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
13. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile.
Abdelazeem AH; El-Saadi MT; Safi El-Din AG; Omar HA; El-Moghazy SM
Bioorg Med Chem; 2017 Jan; 25(2):665-676. PubMed ID: 27916468
[TBL] [Abstract][Full Text] [Related]
15. Selective COX-1 inhibition: A therapeutic target to be reconsidered.
Perrone MG; Scilimati A; Simone L; Vitale P
Curr Med Chem; 2010; 17(32):3769-805. PubMed ID: 20858219
[TBL] [Abstract][Full Text] [Related]
16. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model.
Perrone MG; Vitale P; Panella A; Fortuna CG; Scilimati A
Eur J Med Chem; 2015 Apr; 94():252-64. PubMed ID: 25768707
[TBL] [Abstract][Full Text] [Related]
17. Diarylheterocycle core ring features effect in selective COX-1 inhibition.
Perrone MG; Vitale P; Malerba P; Altomare A; Rizzi R; Lavecchia A; Di Giovanni C; Novellino E; Scilimati A
ChemMedChem; 2012 Apr; 7(4):629-41. PubMed ID: 22278975
[TBL] [Abstract][Full Text] [Related]
18. Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo.
El-Achkar GA; Jouni M; Mrad MF; Hirz T; El Hachem N; Khalaf A; Hammoud S; Fayyad-Kazan H; Eid AA; Badran B; Merhi RA; Hachem A; Hamade E; Habib A
Eur J Pharmacol; 2015 Mar; 750():66-73. PubMed ID: 25617797
[TBL] [Abstract][Full Text] [Related]
19. Design of novel N-phenylnicotinamides as selective cyclooxygenase-1 inhibitors.
Shi L; Li ZL; Yang Y; Zhu ZW; Zhu HL
Bioorg Med Chem Lett; 2011 Jan; 21(1):121-4. PubMed ID: 21144750
[TBL] [Abstract][Full Text] [Related]
20. Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents.
Abdelazeem AH; Abdelatef SA; El-Saadi MT; Omar HA; Khan SI; McCurdy CR; El-Moghazy SM
Eur J Pharm Sci; 2014 Oct; 62():197-211. PubMed ID: 24907682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
